alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CONSOLIDATED
BALANCE SHEET AND CONSOLIDATED STATEMENT OF OPERATIONS FOUND ON PAGES 3 AND 4 OF
THE COMPANY'S FORM 10Q FOR THE YEAR TO DATE MARCH 31, 2000 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                             213
<SECURITIES>                                         0
<RECEIVABLES>                                      260
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                    91
<PP&E>                                           2,689
<DEPRECIATION>                                 (2,299)
<TOTAL-ASSETS>                                   4,641
<CURRENT-LIABILITIES>                            6,092
<BONDS>                                              0
<PREFERRED-MANDATORY>                            3,528
<PREFERRED>                                          0
<COMMON>                                        62,997
<OTHER-SE>                                    (74,177)
<TOTAL-LIABILITY-AND-EQUITY>                     4,641
<SALES>                                          1,667
<TOTAL-REVENUES>                                 1,667
<CGS>                                            1,014
<TOTAL-COSTS>                                    1,014
<OTHER-EXPENSES>                                   415
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               (147)
<INCOME-PRETAX>                                  (565)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              (565)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (565)
<EPS-BASIC>                                     (0.05)
<EPS-DILUTED>                                   (0.05)


</TABLE>
# L_2019250EN.01008301.xml

| 30.9.2019 | EN | Official Journal of the European Union | L 250/83 |
| --- | --- | --- | --- |

30.9.2019

EN

Official Journal of the European Union

L 250/83

---

COUNCIL DECISION (EU) 2019/1612

of 24 September 2019

appointing an alternate member, proposed by the Kingdom of Denmark, of the Committee of the Regions

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 305 thereof,

Having regard to the proposal of the Danish Government,

Whereas:

| (1) | On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020. On 4 June 2018, by Council Decision (EU) 2018/839 (4), Mr Henrik BRADE JOHANSEN was replaced by Ms Karen MELCHIOR as an alternate member. |
| --- | --- |

(1)

On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020. On 4 June 2018, by Council Decision (EU) 2018/839 (4), Mr Henrik BRADE JOHANSEN was replaced by Ms Karen MELCHIOR as an alternate member.

| (2) | An alternate member's seat on the Committee of the Regions has become vacant following the end of the term of office of Ms Karen MELCHIOR, |
| --- | --- |

(2)

An alternate member's seat on the Committee of the Regions has become vacant following the end of the term of office of Ms Karen MELCHIOR,

HAS ADOPTED THIS DECISION:

Article 1

The following is hereby appointed as an alternate member of the Committee of the Regions for the remainder of the current term of office, which runs until 25 January 2020:

| — | Ms EVA BORCHORST MEJNERTZ, Councillor, Municipality of Aarhus. |
| --- | --- |

—

Ms EVA BORCHORST MEJNERTZ, Councillor, Municipality of Aarhus.

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Brussels, 24 September 2019.

For the Council

The President

K. KULMUNI

---

(1)  Council Decision (EU) 2015/116 of 26 January 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 20, 27.1.2015, p. 42).

1

(2)  Council Decision (EU) 2015/190 of 5 February 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 31, 7.2.2015, p. 25).

2

(3)  Council Decision (EU) 2015/994 of 23 June 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 159, 25.6.2015, p. 70).

3

(4)  Council Decision (EU) 2018/839 of 4 June 2018 appointing two members and six alternate members, proposed by the Kingdom of Denmark, of the Committee of the Regions (OJ L 141, 7.6.2018, p. 7).

4

---
§ 310.548 Drug products containing colloidal silver ingredients or silver salts offered over-the-counter (OTC) for the treatment and/or prevention of disease. ( a ) Colloidal silver ingredients and silver salts have been marketed in over-the-counter (OTC) drug products for the treatment and prevention of numerous disease conditions. There are serious and complicating aspects to many of the diseases these silver ingredients purport to treat or prevent. Further, there is a lack of adequate data to establish general recognition of the safety and effectiveness of colloidal silver ingredients or silver salts for OTC use in the treatment or prevention of any disease. These ingredients and salts include, but are not limited to, silver proteins, mild silver protein, strong silver protein, silver, silver ion, silver chloride, silver cyanide, silver iodide, silver oxide, and silver phosphate.
( b ) Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and/or prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act) for which an approved application or abbreviated application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the act.
( c ) Clinical investigations designed to obtain evidence that any drug product containing colloidal silver or silver salts labeled, represented, or promoted for any OTC drug use is safe and effective for the purpose intended must comply with the requirements and procedures governing the use of investigational new drugs as set forth in part 312 of this chapter.
( d ) After September 16, 1999, any such OTC drug product containing colloidal silver or silver salts initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.
[64 FR 44658, Aug. 17, 1999]
<PAGE>   1

                                                                     EXHIBIT 5.1

                        [COOLEY GODWARD LLP LETTERHEAD]

October 1, 1999

Vixel Corporation
11911 Northcreek Parkway South
Bothell, Washington 98011

Ladies and Gentlemen:

     You have requested our opinion with respect to certain matters in
connection with the filing by Vixel Corporation (the "Company") of a
Registration Statement on Form S-1 (the "Registration Statement") with the
Securities and Exchange Commission (the "Commission") covering an underwritten
public offering of up to four million nine hundred forty five thousand
(4,945,000) shares of Common Stock, including six hundred forty five thousand
(645,000) shares of Common Stock which the underwriters have the option to
purchase to cover over-allotments (collectively the "Common Stock").

     In connection with this opinion, we have (i) examined and relied upon the
Registration Statement and related Prospectus, the Company's Restated
Certificate of Incorporation and Bylaws, as currently in effect, and the
originals or copies certified to our satisfaction of such records, documents,
certificates, memoranda and other instruments as in our judgment are necessary
or appropriate to enable us to render the opinion expressed below; and (ii)
assumed that the Restated Certificate of Incorporation, as set forth in Exhibit
3.2 of the Registration Statement, shall have been duly approved and filed with
the office of the Delaware Secretary of State.

     On the basis of the foregoing, and in reliance thereon, we are of the
opinion that the Common Stock, when sold and issued in accordance with the
Registration Statement and related Prospectus, will be validly issued, fully
paid and non-assessable.

     We consent to the reference to our firm under the caption "Legal Matters"
in the Prospectus included on the Registration Statement and to the filing of
this opinion as an exhibit to the Registration Statement.

                                          Very truly yours,

                                          COOLEY GODWARD LLP

                                          By:     /s/ GREGORY B. ABBOTT

                                            ------------------------------------
                                                     Gregory B. Abbott
##### 



Exhibit 32.1 CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Champion Enterprises, Inc. (the
Company) on Form 10-Q for the period ending July 3, 2004 as filed with the
Securities and Exchange Commission on the date hereof (the Report), we,
William C. Griffiths, Chief Executive Officer of the Company, and Phyllis A. Knight,
Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:  (1)
    
    The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)
    
    The information contained in the Report fairly presents, in
all material respects, the financial condition and results of
operations of the Company. /s/
WILLIAM C. GRIFFITHSWilliam
C. GriffithsChief Executive OfficerChampion Enterprises, Inc.August 4, 2004
 /s/ PHYLLIS A. KNIGHTPhyllis A. KnightChief Financial OfficerChampion Enterprises, Inc.August 4, 2004
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 16-6483

UNITED STATES OF AMERICA,

Plaintiff – Appellee,

v.

DEWAYNE ROY WILSON, a/k/a Dub, a/k/a New Jersey, a/k/a 

Jonah James Levant, III,

Defendant - Appellant.

Appeal from the United States District Court for the Western 

District of Virginia, at Charlottesville. Glen E. Conrad, Chief

District Judge. (3:12-cr-00035-GEC-RSB-1; 3:15-cv-80812-GECRSB)

Submitted: September 20, 2016 Decided: September 29, 2016

Before WILKINSON, AGEE, and WYNN, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Dewayne Roy Wilson, Appellant Pro Se. Ronald Mitchell Huber, 

Assistant United States Attorney, Charlottesville, Virginia, for 

Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Dewayne Roy Wilson seeks to appeal the district court’s 

order dismissing his 28 U.S.C. § 2255 (2012) motion. The order 

is not appealable unless a circuit justice or judge issues a 

certificate of appealability. 28 U.S.C. § 2253(c)(1)(B) (2012). 

A certificate of appealability will not issue absent “a 

substantial showing of the denial of a constitutional right.” 

28 U.S.C. § 2253(c)(2) (2012). When the district court denies 

relief on the merits, a prisoner satisfies this standard by 

demonstrating that reasonable jurists would find that the 

district court’s assessment of the constitutional claims is 

debatable or wrong. Slack v. McDaniel, 529 U.S. 473, 484 

(2000); see Miller-El v. Cockrell, 537 U.S. 322, 336-38 (2003). 

When the district court denies relief on procedural grounds, the 

prisoner must demonstrate both that the dispositive procedural 

ruling is debatable, and that the motion states a debatable 

claim of the denial of a constitutional right. Slack, 529 U.S. 

at 484-85. 

We have independently reviewed the record and conclude that 

Wilson has not made the requisite showing. Accordingly, we deny 

a certificate of appealability and dismiss the appeal. We 

dispense with oral argument because the facts and legal 
3

contentions are adequately presented in the materials before 

this court and argument would not aid the decisional process.

DISMISSED
Mr. Eric Fygi 

Deputy General Counsel 

Department of Energy 

Washington, DC 20585 

Dear Deputy General Counsel Fygi: 

u.s. DEPARTMENT OF JUSTICE 

Antitmst Di"ision 

Sharis A. Pozen 

Acting Assistant Attorney General 

RFK Main Justice Building 

950 Pennsylvania Avenue, N.W. 

Washington. D.C. 20530-0001 

(202)514-24011 (202)616-2645 (Fax) 

August 25, 2011 

',.y 

I am responding to your June 27, 2011 letter seeking the views of the Attorney 

General about the potential impact on competition of proposed energy conservation 

standards for residential furnaces, central air conditioners, and heat pumps. Your request 

was submitted under Section 325(o)(2)(B)(i)(V) of the Energy Policy and Conservation 

Act, as amended (ECPA), 42 U.S.C. 6295(o)(2)(B)(i)(5) and 42 U.S.C. 6316(a), which 

requires the Attorney General to make a determination of the impact of any lessening of 

competition that is likely to result from the imposition of proposed energy conservation 

standards. The Attorney General's responsibility for responding to requests from other 

departments about the effect of a program on competition has been delegated to the 

Assistant Attorney General for the Antitrust Division in 28 CFR § 0.40(g). 

In conducting its analysis the Antitrust Division examines whether a proposed 

standard may lessen competition, for example, by substantially limiting consumer choice, 

by placing certain manufacturers at an unjustified competitive disadvantage, or by 

inducing avoidable inefficiencies in production or distribution of particular products. A 

lessening of competition could result in higher prices to consumers, and perhaps thwart 

the intent of the revised standards by inducing substitution to less efficient products. 

We have reviewed the proposed standards contained in the Direct Final Rule (76 

Fed. Reg. 37408, June 27, 2011). We have also reviewed supplementary information 

submitted to the Attorney General by the Department of Energy. Based on this review, 

our conclusion is that the proposed energy conservation standards for residential 

furnaces, residential central air conditioners and heat pumps are unlikely to have a 

I 
Mr. Eric Fygi 

Page 2 

significant adverse impact on competition. In reaching our conclusion, we note that these 

proposed energy standards were adopted from a Consensus Agreement signed by a broad 

cross-section of industry participants.
###### Editorial Note on Part 316

#### Editorial Note:

Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

#### § 316.4 Address for submissions.

All correspondence and requests for FDA action under the provisions of this rule should be addressed as follows: Office of Orphan Products Development, Food and Drug Administration, Bldg. 32, Rm. 5271, 10903 New Hampshire Ave., Silver Spring, MD 20993.

[78 FR 35133, June 12, 2013]
Editorial Note on Part 316
Editorial Note: Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

§ 316.52 Availability for public disclosure of data and information in requests and applications. ( a ) FDA will not publicly disclose the existence of a request for orphan-drug designation under section 526 of the act prior to final FDA action on the request unless the existence of the request has been previously publicly disclosed or acknowledged.
( b ) Whether or not the existence of a pending request for designation has been publicly disclosed or acknowledged, no data or information in the request are available for public disclosure prior to final FDA action on the request.
( c ) Upon final FDA action on a request for designation, FDA will determine the public availability of data and information in the request in accordance with part 20 and § 314.430 of this chapter and other applicable statutes and regulations.
( d ) In accordance with § 316.28, FDA will make a cumulative list of all orphan drug designations available to the public and update such list monthly.
( e ) FDA will not publicly disclose the existence of a pending marketing application for a designated orphan drug for the use for which the drug was designated unless the existence of the application has been previously publicly disclosed or acknowledged.
( f ) FDA will determine the public availability of data and information contained in pending and approved marketing applications for a designated orphan drug for the use for which the drug was designated in accordance with part 20 and § 314.430 of this chapter and other applicable statutes and regulations.
I 

118TH CONGRESS 

2D SESSION H. R. 7364 

To prohibit a person from advertising for sale a product produced or manufactured using the forced labor of individuals in the People’s Republic 

of China, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 15, 2024 

Mr. CURTIS introduced the following bill; which was referred to the Committee 

on Energy and Commerce 

A BILL 

To prohibit a person from advertising for sale a product 

produced or manufactured using the forced labor of individuals in the People’s Republic of China, and for other 

purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘No Forced Labor on 

5 TV Act’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7364 IH

1 SEC. 2. PROHIBITION REGARDING PRODUCTS PRODUCED 

2 USING FORCED LABOR. 

3 (a) PROHIBITION.—A person may not advertise for 

4 sale a covered product. 

5 (b) ENFORCEMENT BY COMMISSION.— 

6 (1) UNFAIR OR DECEPTIVE ACTS OR PRAC7 TICES.—A violation of this section shall be treated 

8 as a violation of a regulation under section 

9 18(a)(1)(B) of the Federal Trade Commission Act 

10 (15 U.S.C. 57a(a)(1)(B)) regarding unfair or decep11 tive acts or practices. 

12 (2) POWERS OF COMMISSION.—The Commis13 sion shall enforce this section in the same manner, 

14 by the same means, and with the same jurisdiction, 

15 powers, and duties as though all applicable terms 

16 and provisions of the Federal Trade Commission Act 

17 (15 U.S.C. 41 et seq.) were incorporated into and 

18 made a part of this section. Any person who violates 

19 this section shall be subject to the penalties and en20 titled to the privileges and immunities provided in 

21 the Federal Trade Commission Act. 

22 (c) DEFINITIONS.—In this section: 

23 (1) COMMISSION.—The term ‘‘Commission’’ 

24 means the Federal Trade Commission. 

25 (2) COVERED PRODUCT.—The term ‘‘covered 

26 product’’ means a product produced or manufacVerDate Sep 11 2014 03:13 Feb 22, 2024 Jkt 049200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H7364.IH H7364

kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 7364 IH

1 tured, in whole or in part, using the forced labor of 

2 individuals in the People’s Republic of China. 

3 (3) FORCED LABOR.—The term ‘‘forced 

4 labor’’— 

5 (A) has the meaning given that term in 

6 section 307 of the Tariff Act of 1930 (19 

7 U.S.C. 1307); and 

8 (B) includes convict labor and indentured 

9 labor under penal sanctions. 

10 (d) EFFECTIVE DATE.—This section shall take effect 

11 on the date that is 180 days after the date of the enact12 ment of this Act. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
<TABLE> <S> <C>

<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                         DEC-31-1996
<PERIOD-START>                            JAN-01-1996
<PERIOD-END>                              SEP-30-1996
<CASH>                                           7886
<INT-BEARING-DEPOSITS>                          84093
<FED-FUNDS-SOLD>                                 3100
<TRADING-ASSETS>                                    0
<INVESTMENTS-HELD-FOR-SALE>                     29456
<INVESTMENTS-CARRYING>                              0
<INVESTMENTS-MARKET>                            14124
<LOANS>                                         78137
<ALLOWANCE>                                      1452
<TOTAL-ASSETS>                                 136963
<DEPOSITS>                                     124982
<SHORT-TERM>                                        0
<LIABILITIES-OTHER>                               845
<LONG-TERM>                                       810
<PREFERRED-MANDATORY>                               0
<PREFERRED>                                         0
<COMMON>                                         1330
<OTHER-SE>                                       2367
<TOTAL-LIABILITIES-AND-EQUITY>                 136963
<INTEREST-LOAN>                                  5096
<INTEREST-INVEST>                                2207
<INTEREST-OTHER>                                  350
<INTEREST-TOTAL>                                 7653
<INTEREST-DEPOSIT>                               2170
<INTEREST-EXPENSE>                               2241
<INTEREST-INCOME-NET>                            7653
<LOAN-LOSSES>                                       0
<SECURITIES-GAINS>                                  0
<EXPENSE-OTHER>                                  7590
<INCOME-PRETAX>                                   852
<INCOME-PRE-EXTRAORDINARY>                        852
<EXTRAORDINARY>                                     0
<CHANGES>                                           0
<NET-INCOME>                                      688
<EPS-PRIMARY>                                       0
<EPS-DILUTED>                                    0.52
<YIELD-ACTUAL>                                      0
<LOANS-NON>                                       884
<LOANS-PAST>                                      121
<LOANS-TROUBLED>                                 1273
<LOANS-PROBLEM>                                     0
<ALLOWANCE-OPEN>                                    0
<CHARGE-OFFS>                                     308
<RECOVERIES>                                      194
<ALLOWANCE-CLOSE>                                   0
<ALLOWANCE-DOMESTIC>                                0
<ALLOWANCE-FOREIGN>                                 0
<ALLOWANCE-UNALLOCATED>                             0
        

</TABLE>
-       - Superintendent of Documents
      - 2023-09-01T17:54:33-0400
      - Government Publishing Office, Washington, DC 20401
      - Government Publishing Office
      - Government Publishing Office attests that this document has not been altered since it was disseminated by Government Publishing Office